MicroGenDX Press Releases

May 25, 2021
MicroGenDX News

MicroGenDX Announces OrthoKEY® Infection Diagnosis and Management for Periprosthetic Joint Infection

ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, has introduced OrthoKEY, an innovative approach to address current clinical shortcomings in the diagnosis of orthopedic infections. OrthoKEY brings accuracy, sensitivity, timeliness, and affordability to PJI diagnostics and management for the clinic and operating room.
May 24, 2021
MicroGenDX News

MicroGenDX is Introducing PerioDX, the First Commercially Available Saliva-Based qPCR+NGS Test for Oral Health

MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, announces its entry into oral microbial diagnostics with the PerioDX test. PerioDX is the first commercially available saliva-based periodontal test to combine quantitative polymerase chain reaction (qPCR) and NGS technology for comprehensive DNA diagnostic results. PerioDX identifies 17 antibiotic resistance genes and all clinically relevant microbes in a sample,1 thereby assisting clinicians both with treatment choices and promoting antimicrobial stewardship.
May 14, 2021
MicroGenDX News

MicroGenDX Selected for 2022 Israeli Space Mission Study

“We’re honored and excited to be part of this study to evaluate the impact of space travel on the urinary microbiome,” says Rick Martin, CEO of MicroGenDX. “MicroGenDX is uniquely qualified to provide this data for analysis that could be the basis for future solutions to astronaut medical care. This work will help shape the future of long-term space missions — including the multi-year Mars mission.”
April 6, 2021
MicroGenDX News

MicroGenDX announces SARS-CoV-2 Whole Genome Variant Identification

New variants continue to emerge rapidly around the globe, causing sequencing efforts at health departments and universities to surveil a small portion of the population and, in some cases, limit their sequencing efforts to breakthrough cases. MicroGenDX is proud to offer the first commercially available, quick-turnaround, economical and accurate option for SARS-CoV-2 whole genome sequencing to combat the spread of emerging variants and gain a better understanding of the epidemiology of SARS-CoV-2.
September 15, 2020

Next Generation Sequencing Predicts Failure in Total Joint Arthroplasty

Disruptive new multicenter research has determined that next generation sequencing (NGS) can reliably predict treatment failure due to periprosthetic joint infection (PJI). MicroGenDX, the High Complexity Laboratory utilized in the study, is upending outdated approaches to infection detection, instead relying on the most up-to-date technologies to not only determine that an infection is present, but to identify the exact micro-organism(s) involved.
Translate »
Shopping Cart
There are no products in the cart!
Continue Shopping